CN113337462A - 改良的干细胞组合物 - Google Patents

改良的干细胞组合物 Download PDF

Info

Publication number
CN113337462A
CN113337462A CN202110474002.4A CN202110474002A CN113337462A CN 113337462 A CN113337462 A CN 113337462A CN 202110474002 A CN202110474002 A CN 202110474002A CN 113337462 A CN113337462 A CN 113337462A
Authority
CN
China
Prior art keywords
cells
cell
stem cells
ang1
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110474002.4A
Other languages
English (en)
Chinese (zh)
Inventor
S·伊泰斯库
P·西蒙斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast International SARL
Original Assignee
Mesoblast International SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901247A external-priority patent/AU2014901247A0/en
Application filed by Mesoblast International SARL filed Critical Mesoblast International SARL
Publication of CN113337462A publication Critical patent/CN113337462A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202110474002.4A 2014-04-07 2015-04-07 改良的干细胞组合物 Pending CN113337462A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901247A AU2014901247A0 (en) 2014-04-07 Improved stem cell composition
AU2014901247 2014-04-07
CN201580018440.2A CN106459913B (zh) 2014-04-07 2015-04-07 改良的干细胞组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580018440.2A Division CN106459913B (zh) 2014-04-07 2015-04-07 改良的干细胞组合物

Publications (1)

Publication Number Publication Date
CN113337462A true CN113337462A (zh) 2021-09-03

Family

ID=53724311

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110474002.4A Pending CN113337462A (zh) 2014-04-07 2015-04-07 改良的干细胞组合物
CN201580018440.2A Active CN106459913B (zh) 2014-04-07 2015-04-07 改良的干细胞组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580018440.2A Active CN106459913B (zh) 2014-04-07 2015-04-07 改良的干细胞组合物

Country Status (9)

Country Link
US (4) US10400218B2 (cg-RX-API-DMAC7.html)
EP (2) EP3129468B1 (cg-RX-API-DMAC7.html)
JP (4) JP6882161B2 (cg-RX-API-DMAC7.html)
KR (2) KR102577698B1 (cg-RX-API-DMAC7.html)
CN (2) CN113337462A (cg-RX-API-DMAC7.html)
AU (4) AU2015243575B2 (cg-RX-API-DMAC7.html)
CA (1) CA2944262C (cg-RX-API-DMAC7.html)
SG (2) SG10202000644TA (cg-RX-API-DMAC7.html)
WO (1) WO2015155187A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012048093A2 (en) 2010-10-08 2012-04-12 Osiris Therapeutics, Inc. Enhanced msc preparations
KR102577698B1 (ko) 2014-04-07 2023-09-12 메조블라스트 인터내셔널 에스에이알엘 개선된 줄기 세포 조성물
WO2015189063A1 (en) * 2014-06-10 2015-12-17 Mesoblast International Sàrl Treatment of immune disorders
JP6231709B1 (ja) * 2016-05-31 2017-11-15 シスメックス株式会社 蛍光画像分析装置および分析方法
EP3619294A1 (en) * 2017-05-04 2020-03-11 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
US12702683B2 (en) 2019-01-03 2026-08-11 Mesoblast International Sárl Method for improving visual acuity
CN113677790B (zh) * 2019-03-26 2024-05-24 普罗米瑟拉疗法公司 用于治疗慢加急性肝衰竭的成体肝祖细胞
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
WO2021176001A1 (en) 2020-03-05 2021-09-10 Mesoblast International Sàrl Method for treating inflammatory lung diseases using mesenchymal lineage precursor or stem cells
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
WO2022173737A1 (en) 2021-02-09 2022-08-18 Millennium Pharmaceuticals, Inc. Methods and compositions for freezing and thawing mammalian cells
JP2025538783A (ja) * 2022-12-09 2025-11-28 メゾブラスト・インターナショナル・エスアーエールエル 事前承認された組成物及び細胞培養方法
AU2023389700A1 (en) * 2022-12-09 2025-07-10 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation
WO2024121821A1 (en) * 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005209688A1 (en) * 1999-07-07 2005-10-06 Angioblast Systems, Inc. Mesenchymal precursor cell
WO2007122233A1 (en) * 2006-04-25 2007-11-01 Vrije Universiteit Brussel Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells
CN101407790A (zh) * 2008-10-30 2009-04-15 浙江大学 一种增强人骨髓间充质干细胞旁分泌能力的处理方法
CN106459913A (zh) * 2014-04-07 2017-02-22 迈索布拉斯特国际有限公司 改良的干细胞组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
JP2003052360A (ja) * 2001-08-20 2003-02-25 Japan Science & Technology Corp 基底膜細胞外基質を用いた間葉系幹細胞の培養方法
KR20050111593A (ko) * 2003-02-19 2005-11-25 가부시키가이샤 디나벡크 겐큐쇼 허혈질환의 치료방법
CN101103101B (zh) * 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US8367405B2 (en) 2005-04-12 2013-02-05 Mesoblast, Inc. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
EP2258413A1 (en) * 2009-06-04 2010-12-08 Université Catholique de Louvain Multi-dimensional biomaterial and method for producing the same.
JP5888670B2 (ja) * 2010-11-18 2016-03-22 国立大学法人東京工業大学 骨芽細胞分化誘導用培養基材、骨芽細胞分化誘導方法、及び骨芽細胞製造方法
CN102899293A (zh) * 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
KR102019540B1 (ko) * 2013-12-18 2019-09-06 아이디에이씨 홀딩스, 인크. 전이중 무선 시스템에서의 간섭 관리 방법, 장치 및 시스템

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005209688A1 (en) * 1999-07-07 2005-10-06 Angioblast Systems, Inc. Mesenchymal precursor cell
WO2007122233A1 (en) * 2006-04-25 2007-11-01 Vrije Universiteit Brussel Preparation of mesenchymal progenitor cells, particularly osteogenic progenitor cells
CN101407790A (zh) * 2008-10-30 2009-04-15 浙江大学 一种增强人骨髓间充质干细胞旁分泌能力的处理方法
CN106459913A (zh) * 2014-04-07 2017-02-22 迈索布拉斯特国际有限公司 改良的干细胞组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALEX ZACHAREK: "Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke", 《J CEREB BLOOD FLOW METAB》, vol. 27, no. 10, XP002590138 *
YENNIFER CORTES: "Isolation and multilineage differentiation of bone marrow mesenchymal stem cells from abattoir-derived bovine fetuses", 《BMC VETERINARY RESEARCH》, no. 9 *

Also Published As

Publication number Publication date
AU2022200640A1 (en) 2022-02-24
US20250136944A1 (en) 2025-05-01
JP7571109B2 (ja) 2024-10-22
US20190345452A1 (en) 2019-11-14
KR20160145066A (ko) 2016-12-19
AU2018200619B9 (en) 2020-05-07
JP2024177516A (ja) 2024-12-19
JP7196216B2 (ja) 2022-12-26
AU2018200619B2 (en) 2020-01-02
US20230030428A1 (en) 2023-02-02
CN106459913B (zh) 2021-05-18
KR20220080023A (ko) 2022-06-14
KR102405663B1 (ko) 2022-06-07
US10400218B2 (en) 2019-09-03
KR102577698B1 (ko) 2023-09-12
WO2015155187A1 (en) 2015-10-15
AU2024203197A1 (en) 2024-05-30
EP3129468A1 (en) 2017-02-15
CA2944262A1 (en) 2015-10-15
US20170107495A1 (en) 2017-04-20
AU2022200640B2 (en) 2024-02-15
CN106459913A (zh) 2017-02-22
AU2015243575B2 (en) 2017-11-02
SG10202000644TA (en) 2020-03-30
EP3129468B1 (en) 2022-09-21
SG11201607925SA (en) 2016-10-28
EP4137560A1 (en) 2023-02-22
JP2017512842A (ja) 2017-05-25
CA2944262C (en) 2023-08-01
AU2020202214B2 (en) 2021-11-18
AU2018200619A1 (en) 2018-02-15
AU2020202214A1 (en) 2020-04-16
US11312941B2 (en) 2022-04-26
JP2021080272A (ja) 2021-05-27
AU2015243575A1 (en) 2016-10-13
JP2023021279A (ja) 2023-02-10
JP6882161B2 (ja) 2021-06-02

Similar Documents

Publication Publication Date Title
JP7571109B2 (ja) 改善された幹細胞組成物
JP7279212B2 (ja) 免疫疾患の治療
CN104204193B (zh) 间充质干细胞的培养
HK40088316A (en) Improved stem cell composition
HK1227933A1 (en) Improved stem cell composition
HK1227933B (en) Improved stem cell composition

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination